Endocrine Abstracts

Background: Fertility outcomes following transsphenoidal surgery (TSS) for pituitary adenoma are unclear, meaning decision-making regarding management options and peri-operative patient counselling is challenging.Objective: To identify the implications of TSS pituitary adenoma resection on the hypothalamic-pituitary-gonadal (HPG) axis and evaluate longer-term fertility outcomes to identify the burden of post-operative infertility.D...

Background: The clinical presentation of non-functioning pituitary adenomas (NFAs) can range from an incidental finding on imaging to pituitary hormone deficiencies and visual compromise.Objective: To assess the clinical presentation of patients who had undergone surgical resection of histologically proven NFAs.Methods: Patients presenting to the University Hospital of Wales, Cardiff, with non-functioning pituitary adenomas (histol...

Background: Neuroendocrine malignancies are heterogeneous cancers with varied clinical outcomes. The molecular landscape driving this heterogeneity has not yet been fully characterized. We aimed to investigate the gene expression profiles of neuroendocrine neoplasms, in relationship to baseline clinicopathological features and clinical outcomes, to elucidate underlying biology and potential therapeutic targets.Methods: Patients with neuroendocrine tumors...

Background: Serum prolactin levels at presentation can be useful in distinguishing between non-functioning pituitary macroadenomas and prolactinomas in order to guide appropriate therapy. Although thresholds have been suggested to distinguish between the two tumour-types, there remains some debate regarding discriminatory levels.Objective: To assess the baseline serum prolactin levels in a series of patients with histologically-proven non-functioning pit...

Background: Carcinoid syndrome (CS), the most common functional neuroendocrine tumor (NET) syndrome, is characterized by watery diarrhea or cutaneous flushing. While somatostatin receptor ligand (SRL) depot injections are mainstay treatments for CS, discomfort with injections and inadequate symptom relief at labeled doses are seen with many patients. Paltusotine is an investigational once-daily, oral, selective SST2 agonist in development for the treatment of acromegaly and CS...